Parkinson's Disease Clinical Trial Landscape
Data updated: May 20, 2026
916 clinical trials tracked since 2008
Parkinson's Disease is a progressive neurodegenerative disorder affecting movement, often characterized by tremors, stiffness, and slow movement. It impacts a significant portion of the aging population and presents a substantial clinical challenge. The clinical trial landscape for Parkinson's Disease demonstrates considerable research activity, with 914 trials registered since 2008, including 185 currently active studies. These active trials span all phases of development, with a notable concentration in Phase 1 (72 active trials out of 338 total) and Phase 2 (100 active trials out of 412 total), suggesting a strong focus on early-stage therapeutic development. Phase 3 trials account for 24 active trials out of 170 total, while Phase 4 trials account for 16 active trials out of 105 total. Industry sponsorship is led by iRegene Therapeutics Co., Ltd., with 5 active trials. Luye Pharma Group Ltd. and Roche each sponsor 3 active trials, followed by AbbVie and H. Lundbeck A/S, each with 2 active trials.
185 active
/
916 total (since 2008)
71
Phase 1 Active
337 total
103
Phase 2 Active
415 total
23
Phase 3 Active
171 total
16
Phase 4 Active
105 total
Top Industry Sponsors
Sorted by active Active Done Failed
iRegene Therapeutics Co., Ltd. 5 0 0
Roche 3 1 0
Luye Pharma Group Ltd. 2 11 0
H. Lundbeck A/S 2 8 2
NeuroDerm Ltd. 2 9 1
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07174310 RECRUITING
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche n=900
NCT06944522 RECRUITING
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics n=102
NCT06553027 ACTIVE NOT RECRUITING
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Cerevance n=330
+ 166 more Phase 3 trials — see full database below
Parkinson's Disease — Trials Started by Year (last 10 years)
2016 52
2017 42
2018 56
2019 53
2020 48
2021 48
2022 47
2023 38
2024 44
2025 58
2026 41
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
iRegene Therapeutics Co., Ltd. 5
Roche 4
Luye Pharma Group Ltd. 13
H. Lundbeck A/S 12
NeuroDerm Ltd. 12
Shanghai Vitalgen BioPharma Co., Ltd. 2
Prevail Therapeutics 2
iCamuno Biotherapeutics Ltd. 2
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 2
Gain Therapeutics, Inc. 2
Active Trials by Phase
Phase 1 71
Phase 2 103
Phase 3 23
Phase 4 16
Enrollment Size Distribution
1-50 511
51-200 264
201-500 76
501-1k 28
1k+ 3
All Industry Sponsors
Sorted by active Active Done Failed
iRegene Therapeutics Co., Ltd. 5 0 0
Roche 3 1 0
Luye Pharma Group Ltd. 2 11 0
H. Lundbeck A/S 2 8 2
NeuroDerm Ltd. 2 9 1
Shanghai Vitalgen BioPharma Co., Ltd. 2 0 0
Prevail Therapeutics 2 0 0
iCamuno Biotherapeutics Ltd. 2 0 0
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 2 0 0
Gain Therapeutics, Inc. 2 0 0
AskBio Inc 2 0 0
AbbVie 1 16 1
Impax Laboratories, LLC 1 10 0
Sumitomo Pharma America, Inc. 1 6 0
Biogen 1 3 3
NCT07174310 RECRUITING
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche n=900
NCT06944522 RECRUITING
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics n=102
NCT06553027 ACTIVE NOT RECRUITING
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Cerevance n=330
NCT07151378 RECRUITING
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
University Hospital Tuebingen n=150
NCT07316296 RECRUITING
Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach
Radboud University Medical Center n=60
NCT07395531 NOT YET RECRUITING
Effect of Repetitive Bihemispheric Anodal Transcranial Direct Current Stimulation on Motor Function of Patients With Parkinson's Disease
Dr. Ram Manohar Lohia Hospital n=30
NCT06976268 RECRUITING
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd. n=550
NCT07207057 RECRUITING
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
University College, London n=1,200
NCT04750226 ACTIVE NOT RECRUITING
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
AbbVie n=118
NCT04664634 RECRUITING
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
Northwestern University n=60
NCT07055958 ACTIVE NOT RECRUITING
Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson's Disease Patients
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh n=74
NCT02339064 ACTIVE NOT RECRUITING
Infusion of Apomorphine: Long-term Safety Study
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals n=99
NCT04006210 ACTIVE NOT RECRUITING
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NeuroDerm Ltd. n=381
NCT06596876 RECRUITING
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
Jiangsu HengRui Medicine Co., Ltd. n=450
NCT05778617 RECRUITING
Ambroxol to Slow Progression in Parkinson Disease
University College, London n=330
NCT05576818 RECRUITING
Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
Tanta University n=66
NCT06120049 RECRUITING
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
prof. dr. Koen Van Laere n=113
NCT04379050 COMPLETED
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
AbbVie n=130
NCT04232969 COMPLETED
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
University College, London n=194
NCT02601586 COMPLETED
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
University Hospital, Toulouse n=67
NCT07466381 COMPLETED
Oxyhydrogen Nanobubble Infusion as a Complementary Therapy in Patients With Parkinsonism
dr. Siti Nurlaela, SpN n=35
NCT06068465 COMPLETED
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Tasly Pharmaceutical Group Co., Ltd n=248
NCT04265209 COMPLETED
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
GE Healthcare n=152
NCT04226248 COMPLETED
CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)
University of Bristol n=600
NCT03568968 COMPLETED
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease
Haukeland University Hospital n=410
NCT04857359 TERMINATED
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Addex Pharma S.A. n=25
NCT05116813 TERMINATED
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Addex Pharma S.A. n=17
NCT04542499 COMPLETED
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
AbbVie n=507
NCT05357989 COMPLETED
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
Annovis Bio Inc. n=523
NCT04152655 WITHDRAWN
A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05611372 WITHDRAWN
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05487300 COMPLETED
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
University of Utah n=40
NCT05001217 COMPLETED
Chinese Herbal Medicine Treatment as Adjunct Therapy for Parkinson's Disease
Hong Kong Baptist University n=160
NCT03149809 COMPLETED
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
VA Office of Research and Development n=77
NCT05418673 TERMINATED
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Biogen n=7
NCT02610231 COMPLETED
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Kyowa Kirin Co., Ltd. n=239
NCT01968031 COMPLETED
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Kyowa Kirin Co., Ltd. n=613
NCT03881371 COMPLETED
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Zambon SpA n=307
NCT02470780 COMPLETED
Treating Bacterial Overgrowth in Parkinson's Disease
University of Cincinnati n=4
NCT02549092 COMPLETED
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
AbbVie n=89
NCT02542696 COMPLETED
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Sumitomo Pharma America, Inc. n=496
NCT03781167 COMPLETED
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
AbbVie n=244
NCT04193527 COMPLETED
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
GE Healthcare n=172
NCT03877510 COMPLETED
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
Impax Laboratories, LLC n=419
NCT04571164 COMPLETED
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Luye Pharma Group Ltd. n=294
NCT03971617 TERMINATED
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
Stony Brook University n=2
NCT01968460 COMPLETED
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Pharma Two B Ltd. n=149
NCT03329508 COMPLETED
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Pharma Two B Ltd. n=544
NCT03670953 COMPLETED
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
Impax Laboratories, LLC n=630
NCT03829657 TERMINATED
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Theravance Biopharma n=203
NCT03391882 COMPLETED
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Sumitomo Pharma America, Inc. n=113
NCT00660673 COMPLETED
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
AbbVie n=262
NCT04380142 COMPLETED
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
AbbVie n=174
NCT01766128 WITHDRAWN
Study of Zonisamide in Early Parkinson Disease
Mazandaran University of Medical Sciences
NCT02337725 COMPLETED
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
Takeda n=244
NCT02337751 COMPLETED
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
Takeda n=198
NCT02337738 COMPLETED
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
Takeda n=404
NCT02337764 COMPLETED
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
Takeda n=222
NCT02153632 TERMINATED
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
Adamas Pharmaceuticals, Inc. n=135
NCT02153645 TERMINATED
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
Adamas Pharmaceuticals, Inc. n=87
NCT03042416 COMPLETED
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta n=400
NCT01736176 COMPLETED
A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease
AbbVie (prior sponsor, Abbott) n=39
NCT02082249 COMPLETED
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
AbbVie n=30
NCT03473522 COMPLETED
Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson's Disease.
Alessandra Tanuri Magalhães n=30
NCT03773796 COMPLETED
Nabilone for Non-motor Symptoms in Parkinson's Disease
Medical University Innsbruck n=22
NCT03759132 COMPLETED
Effects of Transcranial Direct Current Stimulation on Postural Control
Universidade Federal do Piauí n=18
NCT02202551 COMPLETED
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Adamas Pharmaceuticals, Inc. n=223
NCT02799381 COMPLETED
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
AbbVie n=63
NCT00974974 COMPLETED
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
Impax Laboratories, LLC n=471
NCT03876327 COMPLETED
Fecal Microbiota Transplantation As a Potential Treatment for Parkinson's Disease
Soroka University Medical Center n=10
NCT04287543 WITHDRAWN
Melatonin on Clock Genes in Parkinson's Disease
Instituto Mexicano del Seguro Social
NCT02469090 COMPLETED
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
Sumitomo Pharma America, Inc. n=141
NCT02642393 COMPLETED
Study of Urate Elevation in Parkinson's Disease, Phase 3
Michael Alan Schwarzschild n=298
NCT04455555 COMPLETED
Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease
Peking University Third Hospital n=294
NCT04451096 COMPLETED
Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation
National University of Malaysia n=48
NCT01851850 COMPLETED
Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
Rabin Medical Center n=1
NCT02168842 COMPLETED
Efficacy of Isradipine in Early Parkinson Disease
University of Rochester n=336
NCT02782481 WITHDRAWN
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
NeuroDerm Ltd.
NCT01652534 TERMINATED
Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease
Northwestern University n=3
NCT01096186 COMPLETED
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
Impax Laboratories, LLC n=617
NCT01411137 COMPLETED
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
Impax Laboratories, LLC n=43
NCT00880620 COMPLETED
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
Impax Laboratories, LLC n=381
NCT01130493 COMPLETED
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
Impax Laboratories, LLC n=110
NCT02242487 COMPLETED
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Acorda Therapeutics n=325
NCT02006121 COMPLETED
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
Britannia Pharmaceuticals Ltd. n=107
NCT02352363 COMPLETED
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
Acorda Therapeutics n=408
NCT02240030 COMPLETED
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Acorda Therapeutics n=351
NCT03051607 TERMINATED
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Biotie Therapies Inc. n=66
NCT02453386 TERMINATED
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Biotie Therapies Inc. n=449
NCT01283594 COMPLETED
Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off
Biotie Therapies Inc. n=420
NCT03651856 COMPLETED
Atomoxetine for Freezing of Gait in Parkinson's Disease
Medical University of South Carolina n=10
NCT01155479 TERMINATED
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
Merck Sharp & Dohme LLC n=1,022
NCT01155466 COMPLETED
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
Merck Sharp & Dohme LLC n=778
NCT01215227 TERMINATED
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
Merck Sharp & Dohme LLC n=839
NCT01227265 COMPLETED
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
Merck Sharp & Dohme LLC n=476
NCT01479530 COMPLETED
Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
H. Lundbeck A/S n=321
NCT01536574 COMPLETED
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
GlaxoSmithKline n=295
NCT01154166 COMPLETED
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
GlaxoSmithKline n=347
NCT01929317 TERMINATED
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
GlaxoSmithKline n=81
NCT01960842 COMPLETED
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
AbbVie n=31
NCT01646255 COMPLETED
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
UCB Pharma n=346
NCT02091739 COMPLETED
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
Merz Pharmaceuticals GmbH n=184
NCT02136914 COMPLETED
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Adamas Pharmaceuticals, Inc. n=126
NCT02274766 COMPLETED
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Adamas Pharmaceuticals, Inc. n=77
NCT01397422 COMPLETED
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Adamas Pharmaceuticals, Inc. n=83
NCT00664209 TERMINATED
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
University of California, Los Angeles n=64
NCT01014858 TERMINATED
Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease
Newcastle-upon-Tyne Hospitals NHS Trust n=64
NCT00865579 TERMINATED
Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Newron Pharmaceuticals SPA n=964
NCT00658567 COMPLETED
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Inc. n=123
NCT01738178 COMPLETED
Caffeine as a Therapy for Parkinson's Disease
McGill University Health Centre/Research Institute of the McGill University Health Centre n=119
NCT00955318 COMPLETED
Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease
Kyowa Kirin Co., Ltd. n=58
NCT01058291 COMPLETED
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500
Kyowa Kirin Co., Ltd. n=31
NCT01504178 COMPLETED
Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
University Hospital, Toulouse n=28
NCT00856518 COMPLETED
Expiratory Muscle Training for Persons With Neurodegenerative Disease
VA Office of Research and Development n=42
NCT01550484 COMPLETED
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
Avid Radiopharmaceuticals n=170
NCT00823836 COMPLETED
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
GlaxoSmithKline n=302
NCT01662791 COMPLETED
Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
Mayo Clinic n=49
NCT01741701 COMPLETED
A Pilot Study of Oxaloacetate in Subjects With Treated PD
University of Kansas Medical Center n=33
NCT01927055 TERMINATED
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
Chelsea Therapeutics n=61
NCT01388556 COMPLETED
PD4PD:Partnered Dance for Parkinson Disease
Washington University School of Medicine n=62
NCT01227655 COMPLETED
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Bial - Portela C S.A. n=427
NCT01568073 COMPLETED
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Bial - Portela C S.A. n=600
NCT01646268 COMPLETED
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
UCB Pharma n=249
NCT01545414 COMPLETED
Internet-CBT (Cognitive Behavioral Therapy) for Depression and Anxiety in Parkinsons Disease
Karolinska Institutet n=150
NCT00660387 COMPLETED
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
AbbVie (prior sponsor, Abbott) n=35
NCT00357994 COMPLETED
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
AbbVie (prior sponsor, Abbott) n=36
NCT00335153 COMPLETED
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
AbbVie (prior sponsor, Abbott) n=354
NCT00360568 COMPLETED
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
AbbVie (prior sponsor, Abbott) n=62
NCT01556165 COMPLETED
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
H. Lundbeck A/S n=130
NCT01191944 COMPLETED
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
Boehringer Ingelheim n=475
NCT01536015 TERMINATED
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
UCB Pharma n=25
NCT00608231 WITHDRAWN
Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation
Vanderbilt University
NCT00601523 COMPLETED
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Boehringer Ingelheim n=511
NCT01723904 COMPLETED
A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease
UCB BIOSCIENCES GmbH n=90
NCT01628926 COMPLETED
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
Otsuka Pharmaceutical Co., Ltd. n=420
NCT01176240 COMPLETED
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
Chelsea Therapeutics n=225
NCT01174004 COMPLETED
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Inc. n=199
NCT01631825 COMPLETED
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
Otsuka Pharmaceutical Co., Ltd. n=321
NCT01628965 COMPLETED
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
Otsuka Pharmaceutical Co., Ltd. n=143
NCT01439100 COMPLETED
A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain
Mundipharma Research GmbH & Co KG n=172
NCT01268891 COMPLETED
Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
H. Lundbeck A/S n=132
NCT01892176 COMPLETED
Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease
National University Hospital, Singapore n=20
NCT01066442 COMPLETED
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Bioprojet n=273
NCT01036139 COMPLETED
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Bioprojet n=268
NCT00627640 COMPLETED
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Newron Pharmaceuticals SPA n=549
NCT01028586 TERMINATED
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Newron Pharmaceuticals SPA n=507
NCT00740714 TERMINATED
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
Weill Medical College of Cornell University n=600
NCT00943748 COMPLETED
Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease
University Hospital, Lille n=40
NCT00957203 COMPLETED
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Kyowa Kirin Co., Ltd. n=308
NCT00955526 COMPLETED
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Kyowa Kirin Co., Ltd. n=373
NCT01007864 COMPLETED
Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists
Desitin Arzneimittel GmbH n=80
NCT01016470 COMPLETED
Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease
Catalysis SL n=100
NCT00767091 COMPLETED
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
University Hospital, Lille n=40
NCT00748488 COMPLETED
Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease
Radboud University Medical Center n=700
NCT01120392 COMPLETED
Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease
Federal University of Bahia n=40
NCT00623103 COMPLETED
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Novartis n=583
NCT00656253 COMPLETED
Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease
Fudan University n=158
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only